Raver1 links <i>Ripk1</i> RNA splicing to caspase-8-mediated pyroptotic cell death, inflammation, and pathogen resistance
Multiple cell death and inflammatory signaling pathways converge on two critical factors: receptor-interacting serine/threonine kinase 1 (RIPK1) and caspase-8. Careful regulation of these molecules is critical to control apoptosis, pyroptosis, and inflammation. Here, we found a pivotal role of Raver1 as an essential regulator of <i>Ripk1</i> pre-mRNA splicing, expression, and functionality and the subsequent caspase-8-dependent inflammatory cell death. We show that Raver1 influences mRNA diversity primarily by repressing alternative exon inclusion. Macrophages from <i>Raver1</i>-deficient mice exhibit altered splicing of <i>Ripk1</i>. As a result, <i>Raver1</i>-deficient primary macrophages display diminished cell death and decreased interleukin-18 and interleukin-1ß production, when infected with <i>Yersinia</i> bacteria, or by restraining TGF-ß-activated kinase 1 or IKKβ in the presence of lipopolysaccharide, tumor necrosis factor family members, or interferon-γ. These responses are accompanied by reduced activation of caspase-8, Gasdermin D and E, and caspase-1 in the absence of <i>Raver1</i>. Consequently, <i>Raver1</i>-deficient mice showed heightened susceptibility to <i>Yersinia</i> infection. Raver1 and RIPK1 also controlled the expression and function of the C-type lectin receptor Mincle. Our study underscores the critical regulatory role of Raver1 in modulating innate immune responses and highlights its significance in directing in vivo and in vitro inflammatory processes.
Authors
- John Bertin (ORCID: https://orcid.org/0000-0001-9048-1650)
- Michelle A. Kelliher (ORCID: https://orcid.org/0000-0001-9211-3659)
- Jon D. Goguen (ORCID: https://orcid.org/0000-0002-1372-1697)
- Athma A. Pai (ORCID: https://orcid.org/0000-0002-7995-9948)
- Alexandre Dinis (ORCID: https://orcid.org/0000-0002-6813-6380)
- Roland Elling (ORCID: https://orcid.org/0000-0002-2209-4154)
- Megan K. Proulx (ORCID: https://orcid.org/0000-0002-9524-8302)
- Liv Ryan (ORCID: https://orcid.org/0000-0002-7127-6958)
- Katherine A. Fitzgerald (ORCID: https://orcid.org/0000-0003-3175-609X)
- Terje Espevik
- Jesse Lehman (ORCID: https://orcid.org/0000-0002-3729-2866)
- Pontus Ørning (ORCID: https://orcid.org/0000-0002-6177-6916)
- Richard K. Kandasamy (ORCID: https://orcid.org/0000-0002-0894-1222)
- Egil Lien (ORCID: https://orcid.org/0000-0002-8536-2419)
- Boyao Zhang (ORCID: https://orcid.org/0009-0008-4371-005X)
- Leslie Torres-Ulloa (ORCID: https://orcid.org/0000-0002-8026-1926)
Institutions
- Mayo Clinic (US)
- University of Freiburg (DE)
- University of Massachusetts Chan Medical School (US)
- Norwegian University of Science and Technology (NO)
- University Medical Center Freiburg (DE)
- Sanofi (France) (FR)
- GlaxoSmithKline (India) (IN)
- St Olav's University Hospital (NO)
Publication Details
- Journal
- Proceedings of the National Academy of Sciences
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1073/pnas.2420802122
- Citations
- 3
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Kreftforeningen
- National Institute of General Medical Sciences
- National Institute of Allergy and Infectious Diseases